(Q24246262)

English

Natalizumab for induction of remission in Crohn's disease

scientific article

In more languages

default for all languages

No label defined

No description defined

edit

Statements

0 references

0 references

1 reference

Europe PubMed Central

title

Natalizumab for induction of remission in Crohn's disease (English)

0 references

0 references

John K MacDonald

1

0 references

John WD McDonald

series ordinal

2

0 references

publication date

24 January 2007

0 references

published in

Cochrane Database of Systematic Reviews

0 references

cites work

Natalizumab for active Crohn's disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

A randomized placebo-controlled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Natalizumab Induction and Maintenance Therapy for Crohn's Disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Bias in treatment assignment in controlled clinical trials.

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

A controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Attenuation of colitis in the cotton-top tamarin by anti-alpha 4 integrin monoclonal antibody

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Natalizumab plus interferon beta-1a for relapsing multiple sclerosis

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

The effect of anti-alpha4 integrin antibody on brain lesion activity in MS. The UK Antegren Study Group

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

21 January 2018

Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Natalizumab and progressive multifocal leukoencephalopathy

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1002%2F14651858.CD006097.PUB2

retrieved

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD006097.PUB2

0 references

PubMed publication ID

17253580

0 references

(Q24246262)

Natalizumab for induction of remission in Crohn's disease

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)